Kabonib 20mg Tablet

About

Kabonib 20mg Tablet, containing Cabozantinib, is a potent, multi-targeted receptor tyrosine kinase (RTK) inhibitor that plays a crucial role in modern oncology by disrupting several key pathways involved in tumor growth, angiogenesis, and metastasis. It specifically targets MET, VEGFR2, RET, AXL, and KIT, which are often aberrantly activated in various cancers. By inhibiting the phosphorylation and subsequent signaling of these receptors, cabozantinib effectively interferes with the cellular processes that drive cancer cell proliferation, survival, and invasiveness. This mechanism makes it a valuable therapeutic agent for various advanced malignancies, including medullary thyroid cancer, advanced renal cell carcinoma, and hepatocellular carcinoma. Its targeted action helps to slow disease progression, reduce tumor burden, and potentially improve overall patient outcomes, representing a significant advancement in precision cancer therapy. The drug's ability to address multiple oncogenic drivers contributes to its broad utility and efficacy in challenging cancer types.

Uses

• Medullary thyroid cancer (MTC)
• Advanced renal cell carcinoma (RCC)
• Hepatocellular carcinoma (HCC)
• Other solid tumors with specific mutations

Directions For Use

Take orally as directed by your physician, usually once daily on an empty stomach. Do not crush or chew the tablet.

Benefits

• Targets multiple cancer pathways
• Effective in various advanced cancers
• Slows tumor growth and progression
• May improve overall survival
• Oral administration for convenience
• Reduces angiogenesis in tumors

Side Effects

• Diarrhea
• Fatigue
• Nausea
• Vomiting
• Decreased appetite
• Hand-foot syndrome
• Hypertension
• Abdominal pain
• Weight loss
• Dysphonia
• Hypothyroidism
• Proteinuria

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate gastrointestinal side effects or liver toxicity.
• Pregnancy - Not recommended during pregnancy due to potential fetal harm. Effective contraception is required for women of childbearing potential.
• Breastfeeding - Breastfeeding is not recommended during treatment and for a period after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary. Monitor liver function closely.
• Kidney - Use with caution in patients with renal impairment; dose adjustments may be necessary. Monitor kidney function closely.
• Lung - Monitor for pulmonary embolism or other thromboembolic events, though direct lung toxicity is less common.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.